Clinical decision-making insights for haem/oncsDespite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several Share XClinical decision-making insights for haem/oncshttps://pharmaphorum.com/oncology/clinical-decision-making-insights-haem-oncs/
When science and biology combine – the outlook for ADCs in cancer drug developmentAntibody Drug Conjugates (ADCs) are treatments formed by the conjugation of monoclonal antibodies and cytotoxic agents. Although just Share XWhen science and biology combine – the outlook for ADCs in cancer drug developmenthttps://pharmaphorum.com/partner-content-oncology/science-biology-combine-outlook-adcs-cancer-drug-development/
FDA reapproves Pfizer’s Mylotarg leukaemia drugFDA gives green light after 7-year absence Share XFDA reapproves Pfizer’s Mylotarg leukaemia drughttps://pharmaphorum.com/news/fda-reapproves-pfizers-mylotarg-leukaemia-drug/
